1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8754075B2 · kind B2 · utility
3Cited by
1References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 5, 2012 |
| Grant date | Jun 17, 2014 |
| Priority date | — |
| Expiry date | May 24, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides 4-(3-Amino-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamines of formula Ihaving BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.